Replies to post #241410 on Biotech Values

[dewophile]

Sales of their overactive bladder drug seems to be doing well. If you annualize December numbers they are close to 100M at this point. Not bad for a drug that most wrote off given it was entering a crowded space
The 3B investment in Roivant is looking like a good one although still early
I don't know if the company can afford to buy MYOV though so a quick payday may not be in the cards